CERS4

Across TCGA pan-cancer cohorts, CERS4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CERS4 data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CERS4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CERS4 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

PDAC, GBM, and LUAD are the cancer types where CERS4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.681	0.914	.005	20	view →
GBM	OS	Median	All	0.923	0.788	.007	4	view →
LUAD	OS	Quartile	II,III,IV	0.801	0.336	.003	4	view →
LSCC	DFS	Tertile	III,IV	1.000	0.420	.013	3	view →
UCEC	DFS	Median	All	0.925	1.000	.019	2	view →
HNSC	OS	Quartile	IV	0.963	0.676	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CERS4–PDAC (DFS)

Open the PDAC breakdown →